Trial Profile
A dose-finding study of PTK787/ZK 222584 in combination with weekly vinorelbine and trastuzumab as treatment of patients with metastatic breast cancer overexpressing HER-2/neu pre-treated withy at least one line of chemotherapy.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 May 2011
Price :
$35
*
At a glance
- Drugs Vatalanib (Primary) ; Vinorelbine (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics
- 26 May 2011 New trial record